Products - Thyroid disorders | Topic | NICE

Showing 8 products

Date | Title

Guidance programme: Technology appraisal guidanceRemove ‘Guidance programme: Technology appraisal guidance’ filter

Recombinant human parathyroid hormone for treating hypoparathyroidism (terminated appraisal) (TA625)
Product type:
Guidance
Programme:
Technology appraisal guidance
Published:
4 March 2020
Vandetanib for treating medullary thyroid cancer (TA550)
Product type:
Guidance
Programme:
Technology appraisal guidance
Published:
12 December 2018
Lenvatinib and sorafenib for treating differentiated thyroid cancer after radioactive iodine (TA535)
Product type:
Guidance
Programme:
Technology appraisal guidance
Published:
8 August 2018
Cabozantinib for treating medullary thyroid cancer (TA516)
Product type:
Guidance
Programme:
Technology appraisal guidance
Published:
28 March 2018
Etelcalcetide for treating secondary hyperparathyroidism (TA448)
Product type:
Guidance
Programme:
Technology appraisal guidance
Published:
28 June 2017
Cinacalcet for the treatment of secondary hyperparathyroidism in patients with end-stage renal disease on maintenance dialysis therapy (TA117)
Product type:
Guidance
Programme:
Technology appraisal guidance
Published:
24 January 2007
Palopegteriparatide for treating chronic hypoparathyroidism [ID6380]
Status:
In development
Programme:
Technology appraisal guidance
Expected publication date:
16 July 2025
Teprotumumab for treating thyroid eye disease [ID6432]
Status:
In development
Programme:
Technology appraisal guidance
Expected publication date:
20 August 2025